SCHEMBL17291386

SCHEMBL17291386

CC(=O)NC(c1ccc(F)c(C)c1)S(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.42

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
TSHR P16473 2/20 0.42
LMNA P02545 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
PKM P14618 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TP53 P04637 2/20 0.39
CNR1 P21554 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17291310 0.91 MEN1 (0.48) ALDH1A1TSHRLMNAMEN1KMT2A
SCHEMBL17291408 0.85 PKM (0.50) ALDH1A1TSHRLMNAMEN1KMT2A
SCHEMBL1639850 0.84 TP53 (0.51) ALDH1A1LMNAMEN1KMT2APKM
SCHEMBL17291348 0.81 LMNA (0.50) ALDH1A1LMNAMEN1KMT2APKM
SCHEMBL19732921 0.80 MEN1 (0.44) ALDH1A1TSHRLMNAMEN1KMT2A
SCHEMBL9961396 0.78 LMNA (0.49) ALDH1A1TSHRLMNAKMT2APKM
SCHEMBL2763497 0.74 TP53 (0.49) ALDH1A1LMNAMEN1KMT2ATP53
SCHEMBL19732939 0.72 TP53 (0.47) ALDH1A1LMNAMEN1KMT2AHSD17B10
SCHEMBL19732946 0.72 LMNA (0.51) ALDH1A1LMNAPKM
SCHEMBL4097682 0.71 TP53 (0.46) ALDH1A1LMNAMEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2935271-B1 NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 / INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-10-25 EP disclosed
EP-2935271-B1 NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 / INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-10-25 EP disclosed
US-9556179-B2 Substituted imidazoles as casein kinase 1 D/E inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-01-31 US disclosed
US-9556179-B2 Substituted imidazoles as casein kinase 1 D/E inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-01-31 US disclosed
US-9556179-B2 Substituted imidazoles as casein kinase 1 D/E inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-01-31 US disclosed
US-20150344481-A1 NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2015-12-03 US disclosed
US-20150344481-A1 NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2015-12-03 US disclosed
US-20150344481-A1 NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2015-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344481-A1 NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS CSNK1E, CSNK1A1, CSNK1G1 ALDH1A1 2235/4885TSHR 4407/4885LMNA 3866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.